at USC Norris Comprehensive Cancer Center, 1441 Eastlake Ave, Los Angeles, 90033 United States
Treatment of liposarcoma; surgery; immunotherapy
Dr. Tseng is a cancer surgeon with a focus on soft tissue sarcoma and a specific interest in liposarcoma. In addition to treating patients with liposarcoma, Dr. Tseng is developing immunotherapy as an effective treatment option for this disease. He has published numerous articles in the medical literature on liposarcoma, discussing surgical management, current clinical trials, as well as translational studies on the potential for immunotherapy in this disease. Dr. Tseng is originally from Southern California. He obtained his undergraduate and medical degrees at Northwestern University under the Honors Program in Medical Education. He then completed residency in General Surgery at the University of California at San Francisco and fellowship in Surgical Oncology at the University of Texas M.D. Anderson Cancer Center. At M.D. Anderson, he studied sarcoma under the mentorship of Dr. Raphael Pollock. His background in immunology and immunotherapy come from research fellowships at Stanford University and M.D. Anderson. Dr. Tseng sees patients both with and without insurance. His medical practice is active at three locations: USC Keck Hospital and Norris Comprehensive Cancer Center (323) 865-3535 Los Angeles County+USC Medical Center - (323) 409-1500 Hoag Memorial Hospital Presbyterian (949) 764-5389
104 FB users likes Liposarcoma Specialist - William Tseng, MD, set it to 68 position in Likes Rating for Los Angeles, California in Doctor category
Specializing in cosmetic dentistry, teeth whitening, Invisalign, dental implants, and more. Most insurances accepted. Please call to inquire.
We aim to improve the health outcomes and quality of life of the homeless and other vulnerable communities within Los Angeles. Like our Facebook page, and visit our website for more information: http://www.mcp.ucla.edu/ Also, follow us on Twitter for weekly updates: https://twitter.com/MCP_UCLA
USC-Hoag will be opening enrollment very soon for a new immunotherapy clinical trial: "A Phase II Study of Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas (SARC028)." The co-principal investigators will be Dr. James Hu (Medical Oncology) and Dr. William Tseng (Surgical Oncology)